First Author: G.Pappas GREECE
Co Author(s): A. Agelakis G. Bastakis 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate the efficacy of Aflibercept in AMD cases where Rnibizumab and Bevacizumab were unsuccessful to treat
Venizeleio Hospital of Heraklion
We collected the data of 24 AMD cases, previously treated unsuccessfully ( Central Macular Thickness 382.8+/- 55.1 μm) with Ranibizumab and Bevacizumab. We excluded the possibility of RAP or PCV. We evaluated the Central Macular Thickness (OPKO OCT) and the final visual acuity ( ETDRS chart). The follow up period was 6 months.
There was a statistical significant 50.7 μm reduction in CMT, p< 0.01. There was a 3 letters increase in Visual Acuity
Aflibercept may treat cases of AMD where Ranibizumab and Bevacizumab were unable to treat